Published on
May 5, 2025
Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm
A push for advances in precision medicine has introduced more approaches to target mutations in non–small cell lung cancer (NSCLC), such as those in ALK, ROS1, and EGFR, according to Alexis Chidi, MD, PhD, MSPH, who added that the increasingly wide range …
Source:
OncLive
-
Pending
